title: Abnormalities in platelets and vascular endothelial cells induced by glycated lipoproteins.
abstract: We studied the effects of glycated lipoproteins of low- and high-density (LDL and HDL) on platelets and vascular endothelial cells. After pretreatment for 5 minutes at 37 degrees C, the thrombin-induced synthesis of thromboxane B2 in washed platelets was significantly increased by glycated LDL as compared with native LDL (198.9 +/- 16.2 vs 90.3 +/- 29.4 ng/10(9) platelets, n = 8, p less than 0.01). Platelet aggregation was also increased by glycated LDL as compared with native LDL. After treatment with platelet-rich plasma for 5 hours at 37 degrees C, these values were suppressed by native HDL vs the control (buffer), but not by glycated HDL. Abnormalities in the release of 6-keto prostaglandin F1 alpha and lactate dehydrogenase from vascular endothelial cells were also induced by glycated LDL and/or HDL. These observations suggest that abnormalities induced in platelets and vascular endothelial cells by glycated lipoproteins may play an important role in the development of atherosclerosis in patients with diabetes mellitus.
authors.affiliation: Department of Metabolic Medicine, Kumamoto University Medical School, Japan.
authors.forename: H
authors.initials: H
authors.lastname: Takeda
authors.forename: T
authors.initials: T
authors.lastname: Yano
authors.forename: H
authors.initials: H
authors.lastname: Kishikawa
authors.forename: T
authors.initials: T
authors.lastname: Miyata
authors.forename: M
authors.initials: M
authors.lastname: Shinohara
authors.forename: E
authors.initials: E
authors.lastname: Yamaguchi
authors.forename: S
authors.initials: S
authors.lastname: Kobori
authors.forename: J L
authors.initials: JL
authors.lastname: Fan
authors.forename: O
authors.initials: O
authors.lastname: Tokunaga
authors.forename: M
authors.initials: M
authors.lastname: Shichiri
mesh_terms: D015121:6-Ketoprostaglandin F1 alpha / Q000096:biosynthesis; D000328:Adult; D001792:Blood Platelets / Q000187:drug effects* / Q000378:metabolism; D003925:Diabetic Angiopathies / Q000209:etiology; D015232:Dinoprostone / Q000096:biosynthesis; D004730:Endothelium, Vascular / Q000187:drug effects* / Q000378:metabolism; D005260:Female; D017127:Glycation End Products, Advanced; D006031:Glycosylation; D006801:Humans; D066298:In Vitro Techniques; D008075:Lipoproteins, HDL / Q000737:chemistry / Q000494:pharmacology*; D008077:Lipoproteins, LDL / Q000737:chemistry / Q000494:pharmacology*; D008297:Male; D010974:Platelet Aggregation / Q000187:drug effects; D013929:Thromboxane B2 / Q000096:biosynthesis; D000093844:Glycated Proteins
chemical_list: D015121:6-Ketoprostaglandin F1 alpha; D015232:Dinoprostone; D017127:Glycation End Products, Advanced; D008075:Lipoproteins, HDL; D008077:Lipoproteins, LDL; D013929:Thromboxane B2; C051724:glycated lipoproteins, HDL; D000093844:Glycated Proteins; C031797:glycated lipoproteins, LDL